Evidence map›Paper›PMID 25588741›Full record

ArticleGene therapy2015

Potent antitumor activity of Oct4 and hypoxia dual-regulated oncolytic adenovirus against bladder cancer.

C-S Lu, J-L Hsieh, C-Y Lin, H-W Tsai, B-H Su, G-S Shieh, Y-C Su, C-H Lee, M-Y Chang, C-L Wu and 1 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Gene therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

C-S LuDepartment of Biochemistry and Molecular Biology, National Cheng Kung University Medical College, Tainan, Taiwan.
J-L HsiehDepartment of Nursing, Chung Hwa University of Medical Technology, Tainan, Taiwan.
C-Y LinDepartment of Biochemistry and Molecular Biology, National Cheng Kung University Medical College, Tainan, Taiwan.
H-W TsaiDepartment of Biochemistry and Molecular Biology, National Cheng Kung University Medical College, Tainan, Taiwan.
B-H SuDepartment of Biochemistry and Molecular Biology, National Cheng Kung University Medical College, Tainan, Taiwan.
G-S ShiehDepartment of Urology, Tainan Hospital, Department of Health, Executive Yuan, Tainan, Taiwan.
Y-C SuDepartment of Biochemistry and Molecular Biology, National Cheng Kung University Medical College, Tainan, Taiwan.
C-H LeeDepartment of Microbiology, School of Medicine, China Medical University, Taichung, Taiwan.
M-Y ChangInstitute of Medical Sciences, Tzu Chi University, Hualien, Taiwan.
C-L WuDepartment of Biochemistry and Molecular Biology, National Cheng Kung University Medical College, Tainan, Taiwan.
A-L ShiauDepartment of Microbiology and Immunology, National Cheng Kung University Medical College, Tainan, Taiwan.
National Cheng Kung University · TWChina Medical University · TWChung Hwa University of Medical Technology · TWTainan Municipal Hospital · TWTzu Chi University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Most solid tumors undergo hypoxia, leading to rapid cell division, metastasis and expansion of a cell population with hallmarks of cancer stem cells (CSCs). Tumor-selective replication of oncolytic adenoviruses may be hindered by oxygen deprivation in tumors. It is desirable to develop a potent oncolytic adenovirus, retaining its antitumor activity even in a hypoxic environment. We have previously generated an Oct4-dependent oncolytic adenovirus, namely Ad9OC, driven by nine copies of the Oct4 response element (ORE) for specifically killing Oct4-overexpressing bladder tumors. Here, we developed a novel Oct4 and hypoxia dual-regulated oncolytic adenovirus, designated AdLCY, driven by both hypoxia response element (HRE) and ORE. We showed that hypoxia-inducible factor (HIF)-2α and Oct4 were frequently overexpressed in hypoxic bladder cancer cells, and HIF-2α was involved in HRE-dependent and Oct4 transactivation. AdLCY exhibited higher cytolytic activities than Ad9OC against hypoxic bladder cancer cells, while sparing normal cells. AdLCY exerted potent antitumor effects in mice bearing human bladder tumor xenografts and syngeneic bladder tumors. It could target hypoxic CD44- and CD133-positive bladder tumor cells. Therefore, AdLCY may have therapeutic potential for targeting hypoxic bladder tumors and CSCs. As Oct4 is expressed in various cancers, AdLCY may be further explored as a broad-spectrum anticancer agent.

Indexed as

AnimalsAntineoplastic AgentsBasic Helix-Loop-Helix ProteinsCell HypoxiaCell Line, TumorEndothelial PAS Domain-Containing Protein 1HeterograftsHumansMiceOctamer Transcription Factor-3Oncolytic VirusesUrinary Bladder NeoplasmsAntineoplastic AgentsBasic Helix-Loop-Helix ProteinsEndothelial PAS Domain-Containing Protein 1Octamer Transcription Factor-3POU5F1 protein, human

Identifiers

PMID25588741
OpenAlexW2044760086

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.